Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Calidi Biotherapeutics Q2 2024 GAAP EPS $(1.40) Beats $(1.45) Estimate

Author: Benzinga Newsdesk | August 13, 2024 05:39pm
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(1.40) per share which beat the analyst consensus estimate of $(1.45) by 3.45 percent.

Posted In: CLDI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist